Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV.

ABSTRACT:

Objective

To evaluate darunavir and cobicistat pharmacokinetics during pregnancy compared with postpartum and in infant washout samples after delivery.

Design

Nonrandomized, open-label, parallel-group, multicenter phase-IV prospective study of darunavir and cobicistat pharmacokinetics in pregnant women with HIV and their children in the United States.

Methods

Intensive steady-state 24-h pharmacokinetic profiles were performed after administration of 800 mg of darunavir and 150 mg of cobicistat orally in fixed dose combination once-daily during the second trimester, third trimester, and postpartum. Infant washout samples were collected after birth. Darunavir and cobicistat were measured in plasma by validated HPLC-UV and liquid chromatography with tandem mass spectrome

SUBMITTER: Momper JD 

PROVIDER: S-EPMC8173003 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature